Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression

Front Oncol. 2022 Jun 2:12:921667. doi: 10.3389/fonc.2022.921667. eCollection 2022.

Abstract

Hepatocellular carcinoma (HCC) has the third-highest incidence in cancers and has become one of the leading threats to cancer death. With the research on the etiological reasons for cirrhosis and HCC, early diagnosis has been placed great hope to form a favorable prognosis. Non-invasive medical imaging, including the associated contrast media (CM)-based enhancement scan, is taking charge of early diagnosis as mainstream. Meanwhile, it is notable that various CM with different advantages are playing an important role in the different imaging modalities, or even combined modalities. For both physicians and radiologists, it is necessary to know more about the proper imaging approach, along with the characteristic CM, for HCC diagnosis and treatment. Therefore, a summarized navigating map of CM commonly used in the clinic, along with ongoing work of agent research and potential seeded agents in the future, could be a needed practicable aid for HCC diagnosis and prognosis.

Keywords: CECT; MRI; contrast media (CM); hepatocellular carcinoma (HCC); ultrasound.

Publication types

  • Review